Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-5

The 3 platforms with its total of 4 trials have already produced stunning results but the market won't put any value on it. The RAD raising should have put 5c as a floor and yet some still sell for 3.5c. Cashed up financially secured by Lantheus for ever and very promising platforms too but the market ignores that as well. No wonder PH got enough and made the " I hand it over to the US '' - decision. Won't be surprised to see here a 3-4c raise and the sp still sub 2c. CDH17 derisked a lot by starting the trial, pretty sure that asset alone would be worth USD100m if offered to one of the big CAR-T players. The GBM CAR-T CLTX works as well above the current Gold standard and the delivery into the impacted brain area will be improved soon. And MD Anderson Texas wouldn't have engaged CHM if the NKs were crap.

Sometimes one can only shake the head.

GLTA